Picture of Bioatla logo

BCAB — Bioatla News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Bioatla Inc expected to post a loss of 36 cents a share - Earnings Preview

* Bioatla Inc  BCAB.OQ   BCAB.O  is expected to show no
change in
quarterly revenue when it reports  results on November 7 for the
period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Bioatla Inc is for a
loss
of 36 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Bioatla Inc
is
$10.00​, above​ its last closing price of $2.07. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.47       -0.44      -0.44     Met     -0.5
 Mar. 31 2024  -0.54       -0.54      -0.48     Beat    11.4
 Jan. 1 0001   -0.88       -0.79      -0.56     Beat    29.3​
 Sep. 30 2023  -0.82       -0.80      -0.70     Beat    12.5
 ​​Jun.        -0.63       -0.64      -0.75     Missed  -17.2
 30 2023                                                
 Mar. 31 2023  -0.63       -0.63      -0.58     Beat    7.6​
 Jan. 1 0001   -0.62       -0.70      -0.63     Beat    9.7
 Sep. 30 2022  -0.80       -0.80      -0.69     Beat    13.8
 This summary was machine generated November 6 at 05:04 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Bioatla

See all news